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Abstract
Background:  Human cancer vaccines incorporating autologous tumor cells carry a risk of
implantation and subsequent metastasis of viable tumor cells into the patient who is being treated.
Despite the fact that the melanoma cell preparations used in a recent vaccine trial (Mel37) were
gamma-irradiated (200 Gy), approximately 25% of the preparations failed quality control release
criteria which required that the irradiated cells incorporate 3H-thymidine at no more than 5% the
level seen in the non-irradiated cells. We have, therefore, investigated ultraviolet (UV)-irradiation
as a possible adjunct to, or replacement for gamma-irradiation.
Methods: Melanoma cells were gamma- and/or UV-irradiated. 3H-thymidine uptake was used to
assess proliferation of the treated and untreated cells. Caspase-3 activity and DNA fragmentation
were measured as indicators of apoptosis. Immunohistochemistry and Western blot analysis was
used to assess antigen expression.
Results: UV-irradiation, either alone or in combination with gamma-irradiation, proved to be
extremely effective in controlling the proliferation of melanoma cells. In contrast to gamma-
irradiation, UV-irradiation was also capable of inducing significant levels of apoptosis. UV-
irradiation, but not gamma-irradiation, was associated with the loss of tyrosinase expression.
Neither form of radiation affected the expression of gp100, MART-1/MelanA, or S100.
Conclusion: These results indicate that UV-irradiation may increase the safety of autologous
melanoma vaccines, although it may do so at the expense of altering the antigenic profile of the
irradiated tumor cells.
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Background
Cellular immune responses to autologous tumor cells
have been documented in cancer patients including those
with melanoma. Antigens recognized by tumor-specific T
cells have been categorized as cancer-testis antigens, dif-
ferentiation proteins, mutated gene products, widely
expressed proteins, and viral proteins [1-3]. Vaccines
incorporating synthetic forms of these antigens may be
immunogenic, but the ensuing immune response can
only be effective if the tumor in the vaccine recipient
expresses one or more of the antigens present in the vac-
cine. This can be problematic because cancer-testis anti-
gens are expressed only in a subset of tumors [4,5]. and
differentiation antigens are often down-regulated in
metastases [6-11]. Thus, peptide, protein, or DNA-based
vaccines currently being tested can potentially stimulate
immune responses for which there is no target in a partic-
ular patient. Further, such vaccines designed for use in a
general population do not contain unique antigens aris-
ing from mutated gene products as these antigens would
only be useful in the patient whose tumor expresses them
[12-14]. Targeting unique antigens might prove advanta-
geous, however, as many of the altered proteins may play
a role in the malignant phenotype of the cell [13,14].
An ideal synthetic vaccine would contain each of the anti-
gens expressed by the tumor cells of an individual patient,
however, with the limitations of current antigen identifi-
cation technology this is not yet feasible. Until antigen
identification technology can be performed rapidly on a
customized basis for each patient, approaches to vaccina-
tion with unique tumor antigens or otherwise undiscov-
ered antigens will require incorporation of the autologous
tumor tissue in the vaccines. Such approaches include vac-
cination with autologous tumor cells [15,16], RNA
derived from autologous tumor cells [17,18], or heat
shock proteins derived from autologous tumor cells
[19,20]. Autologous tumor cells may be administered as
viable cells alone [15,16], as viable cells with dendritic
cells (DC) [21], or as cell lysates added to DC [22,23].
A concern for patient safety with autologous tumor cell
vaccines is that viable autologous tumor cells could prolif-
erate and metastasize in the host. To prevent this from
occurring after vaccination, a standard approach used in
human clinical trials has been to pre-treat the tumor cells
with 25 to 200 Gy of gamma irradiation [24-29]. We have
enrolled patients in one such melanoma vaccine trial
using autologous tumor cells (Mel37). To provide opti-
mal patient safety within this trial, the tumor cells were
gamma-irradiated (200 Gy) prior to vaccination. As part
of the quality assurance release criteria, a 3H-thymidine
uptake assay was then performed to ensure that the irradi-
ated tumor incorporated 3H-thymidine at no more than
5% of the level found in the non-irradiated tumor.
Our experience with the Mel37 trial has been useful in
establishing additional guidelines and procedures to help
ensure the safety of autologous tumor cell vaccines. In
particular, we demonstrate the resistance of some
patients' metastatic tumor cells to 200 Gy gamma-irradia-
tion as demonstrated by the ability to incorporate 3H-thy-
midine despite being given that dose of radiation. We
therefore investigated ultraviolet (UV) radiation for its
ability to block 3H-thymidine uptake and to induce apop-
tosis of tumor cells. The results from this study demon-
strate that the combination of gamma-irradiation and UV-
irradiation was found to give the best control of tumor cell
proliferation in vitro.
Methods
Tumor tissue collection and human subjects approval
All research involving human subjects and human tissues
was approved by the University of Virginia Institutional
Review Board (IRB# 8577) in accordance with an assur-
ance filed with and approved by the Department of
Health and Human Services (BB-IND# 8932). Tumor
specimens were obtained through the Tissue Procurement
Facility of the University of Virginia.
Tumor cell preparation
Tumor specimens collected sterilely from the operating
room were cut into 2–8 mm thick slices and immersed in
Hanks' balanced salt solution (HBSS, Life Technologies,
Grand Island, NY). The tumor specimen was mechani-
cally dissociated with a sterile scalpel. Remaining tumor
fragments were transferred to a 50 ml conical tube with
RPMI-1640 (Life Technologies) containing 1 mg/ml colla-
genase (Worthington Biochemical Corp., Lakewood, NJ),
10 μg/ml DNAase (Worthington Biochemical Corp.), 2.5
U/ml hyaluronidase (Worthington Biochemical Corp.),
100 μg/ml penicillin G (sodium salt), 100 μg/ml strepto-
mycin sulfate, 0.25 μg/ml amphotericin B, and 5% autol-
ogous serum or human AB serum (Sigma Chemical Co.,
St. Louis, MO) and incubated at room temperature. Dis-
sociated tumor cells were washed by centrifugation with
HBSS. Cell counts with trypan blue were performed to
determine tumor cell viability and yield. Tumor cells were
cryopreserved in 10% DMSO, 90% autologous serum or
human AB serum using a controlled rate freezer.
Assay medium
RPMI-1640 was supplemented with 10% fetal bovine
serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100
μg/ml streptomycin (complete RPMI).
Gamma irradiation of tumor cell suspensions
A Gammacell 3000 Elan (MDS Nordion, Ottawa, ON,
Canada) with a Cesium-137 source used for gamma irra-
diation. Tumor cell suspensions at 1–5 × 106 cells/ml in
complete RPMI were irradiated at 555.5 Gy/min.BMC Cancer 2008, 8:360 http://www.biomedcentral.com/1471-2407/8/360
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Ultraviolet irradiation of tumor cell suspensions
Cell suspensions were plated into 6-well plates at 2–4 × 106
cell/ml in a total volume of 1.5 ml of complete RPMI. The
plate was placed on a UV transilluminator box (UVP, Inc.,
Upland, CA) and exposed to a combination of UVA (84 mJ/
cm2/min) and UVB (26 mJ/cm2/min) for 15 sec to 10 min.
A UVA monitor (UVA-400C, National Biological Corp.,
Twinsburg, OH) and UVB monitor (UVB-500C, National
Biological Corp.) were used to measure the UV dose rate.
Combination ultraviolet and gamma irradiation of tumor 
cells
Cells were first exposed to UV irradiation and then
exposed to gamma irradiation as described above.
Assay of 3H-thymidine incorporation after irradiation
Tumor cell suspensions in complete RPMI were plated in
5–6 replicates at 20,000–50,000 cells/200 μl in flat-bot-
tom 96-well plates (Costar, Lowell, MA) and incubated at
37°C in a humidified, 5% CO2 incubator for 5 days. One
μCi of 3H-thymidine in 25 μl of complete RPMI was then
added to each well and the incubation continued for an
additional 18–24 h. Cells were then harvested using a
MACH IIIM Harvester 96 (Tomtec, Hamden, CT) and the
amount of incorporated 3H-thymidine in counts per
minute (CPM) was determined using a 1450 MicroBeta
Trilux Liquid Scintillation and Luminescence Detector
(PerkinElmer, Boston, MA). Background 3H-thymidine
incorporation was initially determined with wells con-
taining only complete medium while later experiments
used wells containing a comparable number of cells that
had been subjected to three freeze-thaw cycles (freezing in
liquid nitrogen followed by thawing in a 37°C water
bath). As a control, the lymphoblastoid cell line K562 was
treated in a similar fashion. Incorporated 3H-thymidine
was determined as: CPMcells - CPMbackground. Percent maxi-
mal  3H-thymidine incorporation was determined as:
[(CPMirradiated - CPMbackground)/(CPMnon-irrdiated - CPMback-
ground)] × 100.
Apoptosis assays
Caspase-3 activity was measured as previously described
using DEVD-AFC (Calbiochem, San Diego, CA) as the
substrate [30]. DNA fragmentation was measured using a
Cell Death Detection ELISAPLUS kit (Roche, Indianapolis,
IN) according to the manufacturer's instructions.
Immunohistochemistry
To evaluate antigen expression at various time points after
irradiation, tumor cell suspensions were pelleted by cen-
trifugation. Cell blocks were made by pelleting the cells,
fixing them with 10% formalin, and then embedding
them in paraffin. Immunohistochemistry stains were per-
formed by the Pathology Department using clinical-grade
antibodies to gp100 (HMB45, Dako, Carpinteria, CA),
tyrosinase (T311, Vector Laboratories, Burlingame, CA),
MART-1/MelanA (A103, Dako), and S100 (Dako) and the
slides were read by a pathologist (MWT).
Western blot analysis
Cells were harvested and lysates prepared using NP-40
lysis buffer [31]. Protein concentration was determined
using a BCA Protein Assay Kit (Pierce, Rockford, IL). Pro-
teins (40 μg/lane) were resolved on 4–12% Bis-Tris poly-
acrylamide gels and then transferred to PVDF membranes
(Pierce, Rockford, IL). After blocking with 1% bovine
serum albumin, the membranes were probed with a rab-
bit polyclonal antisera to tyrosinase (clone H-109, Santa
Cruz Biotechnology, Santa Cruz, CA) and a mouse mon-
oclonal antibody to GAPDH (clone 6C5, Millipore, Biller-
ica, MA). Peroxidase-linked sheep anti-mouse and
donkey-anti-rabbit antisera (Amersham Biosciences, Pis-
cataway, NJ) in conjunction with the SuperSignal West
Pico Chemiluminescent substrate (Pierce) were used to
detect binding of the primary antibodies.
Results
Proliferation of gamma-irradiated melanoma cells 
prepared for autologous vaccination
Mel37 was an autologous melanoma vaccine trial con-
ducted at the University of Virginia (UVA). To minimize
the possibility of outgrowth of the tumor cells in the vac-
cine recipient, the tumor cells were gamma irradiated
(200 Gy) prior to administration. The irradiated tumor
cells were then tested for their ability to incorporate 3H-
thymidine in comparison to the non-irradiated control
sample. As part of the lot vaccine release criteria, the 3H-
thymidine incorporation of the irradiated cells had to be
less than 5% of the 3H-thymidine incorporation of the
corresponding non-irradiated cells. Vaccine preparations
that failed to meet those criteria were not used.
Tumors from thirty-three melanoma patients were
included in the study and demonstrated a 9,300-fold
range of 3H-thymidine incorporation, varying from 18 to
170,014 CPM (Figure 1A). Gamma-irradiation (200 Gy)
reduced the 3H-thymidine incorporation of twenty-five
(76%) of these samples below 5% of the non-irradiated
control samples (Figure 1B). The remaining eight irradi-
ated vaccines (24%) had a mean 3H-thymidine incorpora-
tion of 28% (median 17%, range, 8%–63%) in
comparison to the non-irradiated control samples. Nota-
bly, the 3H-thymidine incorporation of irradiated tumor
cells from three patients exceeded 40% of the correspond-
ing non-irradiated samples. Among the eight specimens
failing the lot release criteria, five were retested from one
to three times with the same results (data not shown).
The fact that 200 Gy of gamma-irradiation failed to reduce
the  3H-thymidine incorporation of eight of thirty-threeBMC Cancer 2008, 8:360 http://www.biomedcentral.com/1471-2407/8/360
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samples below 5% of the non-irradiated controls
prompted us to determine if a more effective means could
be found to reduce the 3H-thymidine incorporation of the
treated samples. These studies, which follow, were con-
ducted with melanoma cell lines rather than fresh patient
samples, as cells from the lines are not limiting in num-
bers.
Dose response of gamma-irradiation on the proliferative 
capacity of melanoma cell lines
The inability of 200 Gy of gamma-irradiation to decrease
3H-thymidine incorporation of melanoma cells to less
than 5% of that seen in the corresponding non-irradiated
controls could be the result of using too low a dose of irra-
diation, although the dose chosen is at the upper limit of
what has been used in other studies [24-29]. A gamma-
irradiation dose response experiment with four different
melanoma cell lines was therefore conducted to deter-
mine if 200 Gy is a reasonable dose. The results indicate
that 3H-thymidine rapidly decreased through about 50 Gy
and then remained at a low, but measurable level through
200 Gy (Figure 2A). In no case, however, did the 3H-thy-
midine of the irradiated samples relative to the non-irra-
diated samples decrease below 5% (DM6 = 28%, DM93 =
53%, VMM39 = 14%, VMM86 = 23%).
Dose response of UV-irradiation on the 3H-thymidine 
uptake of melanoma cell lines
The effect of UV-irradiation on the 3H-thymidine uptake
of melanoma cells was next tested. Adherent monolayers
of cells in 6-well plates were exposed to a UV light source
for varying amounts of time and at a delivery rate of 84
mJ/cm2/min UVA and 26 mJ/cm2/min UVB. Although
melanoma cell line DM93 was less sensitive to lower
doses of UV-irradiation than were the other three
melanoma cell lines, two minutes of UV-irradiation was
sufficient to reduce the 3H-thymidine uptake of the irradi-
ated cells to 1.5% or less of the corresponding non-irradi-
ated cell line (Figure 2B).
Combined effect of gamma-irradiation and UV-irradiation 
on the 3H-thymidine uptake capacity of melanoma cell 
lines and fresh melanoma cells
Melanoma cell lines were next subjected to 0 – 10 min of
UV-irradiation followed by 0 – 200 Gy gamma-irradiation
(Figure 3). As in previous experiments, gamma-irradiation
alone did not reduce 3H-thymidine uptake below 5% of
that of the non-irradiated controls. In contrast, as little as
one minute of UV-irradiation was sufficient to drop the
3H-thymidine uptake of each of the cell lines to less than
0.5% of the non-irradiated control. Because the reduction
in  3H-thymidine uptake with UV-irradiation was nearly
complete, the combination of UV-irradiation and
gamma-irradiation did not show any additive or synergis-
tic effects within the dose ranges chosen.
Five melanoma cell lines were further treated with
gamma-irradiation (200 Gy) alone, UV-irradiation alone
(2 min), or a combination of the two (Figure 4). Relative
3H-thymidine incorporation of melanoma cells prior to and  following treatment with 200 Gy gamma-irradiation Figure 1
3H-thymidine incorporation of melanoma cells prior 
to and following treatment with 200 Gy gamma-irra-
diation. Human melanoma deposits were resected surgically 
and the tumors rendered into single cell suspensions by 
mechanical and enzymatic dissociation. The cell suspensions 
were then prepared into a tumor cell vaccine and split into 
samples receiving or not receiving 200 Gy gamma-irradiation. 
The non-irradiated and irradiated cells were then cultured in 
vitro for five days prior to the addition of 3H-thymidine for 18 
to 24 hr. (A) Proliferation in the absence of gamma-irradia-
tion. Samples ordered from lowest to highest proliferation. 
(B) Proliferation following treatment with 200 Gy gamma-
irradiation. The data are presented as percent maximal 3H-
thymidine incorporation in comparison to the non-irradiated 
control. Samples are ordered as in (A). The dashed horizon-
tal bar indicates 5% maximal 3H-thymidine incorporation.BMC Cancer 2008, 8:360 http://www.biomedcentral.com/1471-2407/8/360
Page 5 of 11
(page number not for citation purposes)
to the non-irradiated controls, gamma-irradiation
reduced the 3H-thymidine uptake to 31% (range = 9 –
71%), UV-irradiation reduced the 3H-thymidine uptake to
2.2% (range = 0.2–4.8%), and the combination of UV and
gamma-irradiation reduced the 3H-thymidine uptake to
1.1% (range = 0.0–1.9%). Although in each case, UV-irra-
diation reduced the 3H-thymidine uptake to less than 5%,
the combination of UV- and gamma-irradiation reduced
3H-thymidine uptake further.
Three single cell suspensions of fresh melanoma cells were
also treated individually or in combination with gamma-
irradiation (200 Gy) and UV-irradiation (2 min) (Figure
5). Gamma-irradiation of sample VMM392 did not
reduce its 3H-thymidine uptake below 5% of that of the
non-irradiated control, while UV-irradiation either alone
or in combination with gamma-irradiation reduced its
3H-thymidine uptake below 5%. For each of the three
samples tested, the combination of gamma-irradiation
and UV-irradiation decreased 3H-thymidine uptake to a
greater extent than did use of either form of irradiation
alone.
Effect of gamma-irradiation and UV-irradiation on the 
induction of apoptosis
Eight hours following treatment with gamma-irradiation,
UV-irradiation or a combination of both forms of radia-
tion, the melanoma cell lines VMM39 and VMM86 were
evaluated for apoptosis by caspase and DNA fragmenta-
tion assays (Figure 6A, 6B). Gamma-irradiation by itself
Effect of gamma-irradiation and UV-irradiation dose titration  on the 3H-thymidine incorporation of melanoma cell lines Figure 2
Effect of gamma-irradiation and UV-irradiation dose 
titration on the 3H-thymidine incorporation of 
melanoma cell lines. Melanoma cell lines, either untreated 
or treated with the indicated dose of (A) gamma-irradiation 
or (B) UV-irradiation, were cultured in vitro for five days 
prior to the addition of 3H-thymidine for 18 to 24 hr.
Control of melanoma cell line 3H-thymidine incorporation  after combination gamma-irradiation andUV-irradiation Figure 3
Control of melanoma cell line 3H-thymidine incorpo-
ration after combination gamma-irradiation andUV-
irradiation. Melanoma cell lines (A) VMM39 and (B) 
VMM86 were non-irradiated or treated with varying combi-
nations of gamma-irradiation or UV-irradiation. The cell lines 
were then cultured in vitro for five days prior to the addition 
of 3H-thymidine for 18 to 24 hr. The dashed horizontal bar 
indicates 5% maximal 3H-thymidine incorporation.BMC Cancer 2008, 8:360 http://www.biomedcentral.com/1471-2407/8/360
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led to a small increase in caspase detection with
melanoma line VMM39, while UV-irradiation, either
alone or in combination with gamma-irradiation led to
higher levels of detectable caspase with VMM39 (Figure
6A). Similar results were obtained with melanoma line
VMM86 except that gamma-irradiation alone did not
result in an increase in the detectable caspase. Gamma-
irradiation by itself did not increase (VMM39) or only
slightly increased (VMM86) DNA fragmentation over that
seen in untreated controls (Figure 6B). UV-irradiation
induced DNA fragmentation in both cell lines, and the
combination of both types of radiation led to the largest
increases in DNA fragmentation.
Tumor viability following gamma-irradiation and UV-
irradiation
To determine the approximate time after radiation that
human tumor cells remain viable, the melanoma cell line
VMM39 was irradiated, cultured in vitro for up to seventy-
nine hours, and evaluated for viability by trypan blue
exclusion (Figure 7). Cells treated with gamma-irradiation
alone remained greater than 80% viable seventy-nine
hours post treatment and had comparable viability to that
of the untreated cells. Conversely, cells treated with UV-
irradiation or a combination of UV- and gamma-irradia-
tion demonstrated a marked decrease in viability within
24 hours of treatment, and were less than 35% viable
within seventy-nine hours following treatment. The mor-
phology of the treated and untreated cells five days post-
treatment is consistent with the observed viability (Figure
8). The VMM39 melanoma cells remained adherent five
days after gamma-irradiation, but all cells had lost adher-
ence by five days after UV-irradiation, consistent with
induction of apoptosis in the vast majority of tumor cells.
Treatment of the cells with both gamma-irradiation and
UV-irradiation did not produce changes in morphology or
adherence that were distinguishable from UV-irradiation
treatment alone.
Effect of gamma-irradiation and UV-irradiation on the 
stability of antigenic proteins
To evaluate if the treatment of melanoma cell lines DM6
and DM93 with gamma-irradiation and/or UV-irradiation
impacts the expression of three common shared
melanoma antigens (gp100, tyrosinase, MART-1) and the
melanoma marker S100, the cell lines were irradiated and
then cultured an additional twenty-nine hours. Cell
blocks were then prepared and antigen expression deter-
mined by immunohistochemistry (Table 1). In compari-
son to untreated controls, the treatments, either alone or
in combination, did not affect the expression of gp100,
MART-1, and S100. In contrast, UV-irradiation, either
alone or in combination with gamma-irradiation, ren-
dered tyrosinase undetectable using the tyrosinase-spe-
cific antibody T311.
Control of melanoma cell line 3H-thymidine incorporation  after combination gamma-irradiation andUV-irradiation Figure 4
Control of melanoma cell line 3H-thymidine incorpo-
ration after combination gamma-irradiation andUV-
irradiation. Melanoma cell lines were non-irradiated, 
gamma-irradiated (200 Gy), UV-irradiated (5 min), or both 
gamma-irradiated (200 Gy) and UV-irradiated (5 min). The 
cell lines were then cultured in vitro for five days prior to the 
addition of 3H-thymidine for 18 to 24 hr. The data are pre-
sented as percent maximal 3H-thymidine incorporation in 
comparison to the non-irradiated control. The dashed hori-
zontal bar indicates 5% maximal 3H-thymidine incorporation.
Control of melanoma vaccine preparation 3H-thymidine  incorporation after combination gamma-irradiation andUV- irradiation Figure 5
Control of melanoma vaccine preparation 3H-thymi-
dine incorporation after combination gamma-irradi-
ation andUV-irradiation. Melanoma cells prepared for 
vaccination were non-irradiated, gamma-irradiated (200 Gy), 
UV-irradiated (5 min), or both gamma-irradiated (200 Gy) 
and UV-irradiated (5 min). The cell lines were then cultured 
in vitro for five days prior to the addition of 3H-thymidine for 
18 to 24 hr. The data are presented as percent maximal 3H-
thymidine incorporation in comparison to the non-irradiated 
control. The dashed horizontal bar indicates 5% maximal 3H-
thymidine incorporation.BMC Cancer 2008, 8:360 http://www.biomedcentral.com/1471-2407/8/360
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The effect of UV-irradiation on tyrosinase expression was
further investigated by performing Western blot analysis
(Figure 9). Cell lysates were prepared from cells treated
twenty-nine hours earlier with UV-irradiation or from
untreated control cells. Tyrosinase protein expression was
detected in untreated DM6 and DM93 melanoma lines,
with DM6 expressing higher amounts of tyrosinase than
DM93. Tyrosinase protein expression was detected at sig-
nificantly lower levels in the corresponding UV-irradiated
cells. GAPDH expression is roughly equivalent in the dif-
ferent samples indicating that a similar amount of protein
is present in each lane.
Discussion
The first requirement of a new therapy is that it be safe.
Although cancer vaccines are generally considered safe,
vaccines incorporating autologous tumor carry a risk of
implanting tumor cells that are capable of growth and dis-
semination in the patient. Such a risk has been demon-
Induction of apoptosis in melanoma cell lines following  gamma-irradiation and/or UV-irradiation Figure 6
Induction of apoptosis in melanoma cell lines follow-
ing gamma-irradiation and/or UV-irradiation. 
Melanoma cells prepared for vaccination were non-irradi-
ated, gamma-irradiated (200 Gy), UV-irradiated (5 min), or 
both gamma-irradiated (200 Gy) and UV-irradiated (5 min). 
The cell lines were then cultured in vitro for eight hours prior 
to assaying (A) caspase activity or (B) DNA fragmentation.
Melanoma cell viability after irradiation Figure 7
Melanoma cell viability after irradiation. The melanoma 
cell line VMM39 was evaluated by trypan blue exclusion for 
the persistence of viable cells at multiple time points after 
UV-irradiation alone (5 min), gamma-irradiation alone (200 
Gy), combined UV-irradiation (5 min) and gamma-irradiation 
(200 Gy), or no treatment.
Adherence and morphology of melanoma cell line VMM39  following gamma-irradiation and/or UV-irradiation Figure 8
Adherence and morphology of melanoma cell line 
VMM39 following gamma-irradiation and/or UV-irra-
diation. VMM39 was (A) non-irradiated, (B) gamma-irradi-
ated (200 Gy), (C) UV-irradiated (5 min), or (D) both 
gamma-irradiated (200 Gy) and UV-irradiated (5 min). The 
cell lines were then cultured in vitro for five days prior to 
microscopic evaluation. Representative areas of the cell cul-
ture surface are shown.BMC Cancer 2008, 8:360 http://www.biomedcentral.com/1471-2407/8/360
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strated by a vast experience with transfer of tumors
between syngeneic mice, but for obvious reasons, such
studies have not been done in humans. There are, how-
ever, anecdotal reports that highlight the risk. These anec-
dotes come from older literature and involve allogeneic
tumor cell transfer into patients with decreased immune
competence. In one case an elderly woman was injected
with her daughter's melanoma cells, which subsequently
metastasized and caused her death [32]. In another case, a
volunteer with impaired health developed metastases
from transferred allogeneic tumor cells [33,34]. There are
also documented cases of transfer of malignancy into an
organ transplant recipient when the transplanted organ
contained occult malignant cells [35]. These cases indicate
that there is not only a theoretical risk, but also a finite
risk, of tumor outgrowth in an individual receiving either
autologous or allogeneic tumor cells. To guard against this
risk, pretreatment of tumor cells by gamma-irradiation is
a standard part of the preparation of autologous and allo-
geneic tumor vaccines.
There is no standard dose of gamma-irradiation with
which to pre-treat tumor cells in vitro prior to their use in
a vaccine, as previous studies have used gamma radiation
ranging from 25 to 200 Gy [24-29]. In situ, gamma radia-
tion is used clinically to control solid tumors, and is rarely
able to destroy all tumor cells when delivered in multiple
fractions to a total 50–60 Gy dose that is tolerated by sur-
rounding tissues. With stereotactic radiation (gamma
knife), high single doses in the range of 20 Gy are deliv-
ered to tumor cell deposits. This is much more effective at
tumor destruction, but 20–25% of patients have tumors
that fail to be controlled even after that large a dose of
radiation [36,37]. Thus, there is ample evidence from clin-
ical experience that high doses of gamma radiation may
be inadequate to prevent human tumor cells from prolif-
erating. To error on the side of caution, we chose 200 Gy
of gamma-irradiation as the standard dose at which to
pre-treat melanoma cells prior to use in an autologous
vaccine preparation.
Following gamma-irradiation, the cells were tested for
their ability to proliferate as measured by 3H-thymidine
incorporation. The lot release criteria specified in the IND
under which the Mel37 trial was conducted required that
when measured between five and six days following
gamma-irradiation, the 3H-thymidine incorporation of
the irradiated cells be less than 5% of the 3H-thymidine
incorporation of the non-irradiated cells. This criterion
likely errs on the side of being too stringent, as cells with
damaged chromosomes can incorporate 3H-thymidine to
a limited extent even though they are incapable of prolif-
erating, and some tumor cells damaged by radiation can
continue to proliferate for a period of time before they die
Table 1: Antigen expression in melanoma cell lines twenty nine hours following UV and/or gamma-irradiation*
% Antigen Expression†
gp100 Tyrosinase MART-1/MelanA S100
Treatment DM6 DM93 DM6 DM93 DM6 DM93 DM6 DM93
Non-irradiated 98% 100% 25% 98% 90% 90% 100% 100%
UV 98% 100% < 1% 5% 70% 85% 100% 100%
Gamma 100% 100% 30% 98% 80% 85% 100% 100%
UV + Gamma 98% 100% < 1% 1% 75% 85% 100% 100%
* Melanoma cells were non-irradiated, gamma-irradiated (200 Gy), UV-irradiated (5 min), or both gamma-irradiated (200 Gy) and UV-irradiated (5 
min).
†The percent of cells staining for gp100 expression, tyrosinase, MART-1/MelanA, and S100 expression was assessed by immunohistochemistry.
Tyrosinase protein expression followingUV-irradiation Figure 9
Tyrosinase protein expression followingUV-irradia-
tion. Melanoma cell lines DM6 and DM93 were either non-
irradiated or UV-irradiated (5 min), and then cultured an 
additional 29 h. Detergent lysates were then prepared and 
tyrosinase expression (~70 kDa) and GAPDH expression 
(~37 kDa) determined by Western blot analysis.BMC Cancer 2008, 8:360 http://www.biomedcentral.com/1471-2407/8/360
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[38]. Thus, some vaccine preparations will not be used
because of the inability to demonstrate the loss of prolif-
eration in a short term assay. Alternatives to 3H-thymidine
incorporation exist, but they are problematic as well.
Trypan blue dye exclusion and counting is subject to a
high rate of inter- and intra-operator error. Clonogenic
assays are complicated by the fact that even in the absence
of irradiation, only about 30–40% of all fresh melanoma
samples yield a cell line (unpublished observations), thus
lack of tumor outgrowth from a sample following irradia-
tion doesn't necessarily reflect the results of irradiation.
Likewise, xenografts into immunodeficient mice yield less
than 100% outgrowth, and can require months to over a
year for a tumor to become established [39].
When tumor cells from thirty-three melanoma patients
were gamma-irradiated and subsequently tested for 3H-
thymidine incorporation, eight of the preparations did
not meet the release criteria (Figure 1). Five of these eight
samples were among the nine samples with the lowest 3H-
thymidine incorporation. This observation is consistent
with that fact that cells do not always die immediately fol-
lowing radiation treatment but may first need to undergo
several rounds of cell division as their genome becomes
increasingly unstable [40]. Cells incorporating little 3H-
thymidine are unlikely to be undergoing mitosis at a high
rate and thus less likely to acquire the genomic instability
necessary to lead to cell death. Although less often than
cells with a low proliferative capacity, some samples with
an initial high proliferative capacity clearly retained the
ability to proliferate following gamma-irradiation. These
results indicate that treatment with 200 Gy of gamma irra-
diation is not always sufficient to block the incorporation
of 3H-thymidine into the DNA of melanoma samples, and
that approximately 25% of the samples will fail a release
criterion that requires the 3H-thymidine incorporation of
the gamma-irradiated sample to be less than 5% of that
obtained with the corresponding non-irradiated sample.
Of the twenty-eight vaccine lots that were released for
immunization, none resulted in outgrowth of the tumor
at the site of immunization. Interestingly, while other
studies have treated the autologous tumor to be used in
vaccines with 25 to 200 Gy of irradiation [24-29], none of
the studies apparently incorporated a release criterion
demonstrating that the irradiation had substantially
impacted on the ability of the cells to proliferate. Also,
none of those studies reported outgrowth of the immu-
nizing tumor at the injection site.
Although it is feasible to measure post-radiation 3H-thy-
midine incorporation capacity and to exclude patients
from protocols whose tumors demonstrate incorporation
after gamma-irradiation as was done for the Mel37 clini-
cal trial, we wanted to develop a protocol that would more
reliably block 3H-thymidine incorporation in the irradi-
ated tumor cells. UV-irradiation, which is known to
induce apoptosis [40-42], was therefore tested as an
adjunct to gamma-irradiation.
Treatment of melanoma cell lines and patient samples
with UV-irradiation (168 mJ/cm2 UVA and 52 mJ/cm2)
alone or in combination with gamma-irradiation (200
Gy) is more effective at reducing 3H-thymidine incorpora-
tion than is treatment with gamma-irradiation alone (Fig-
ure 3, 4, 5). This finding is consistent with the results of
the cell viability assay which demonstrates that UV-irradi-
ation either alone or in combination with gamma-irradi-
ation induces a significant amount of death one day
following treatment, while gamma-irradiation alone has
no effect on viability at least through three days following
treatment (Figure 7). Although in most cases UV-irradia-
tion may be sufficiently effective on its own to reduce 3H-
thymidine incorporation below that of 5% of the non-
irradiated control, the combination of gamma-irradiation
and UV-irradiation adds an extra layer of security in min-
imizing the possibility of tumor outgrowth following vac-
cination.
Gamma-irradiation can induce apoptosis in tumor cells
[40,43,44], but 200 Gy of gamma-irradiation induced lit-
tle to no apoptosis in the melanoma cell lines VMM39
and VMM86 when they were tested eight hours post-irra-
diation (Figure 6). This was true whether caspase was
measured as an indicator of early apoptosis or DNA frag-
mentation was measured as an indicator of late apoptosis.
Conversely, UV-irradiation, either alone or in combina-
tion with gamma-irradiation, induced apoptosis as meas-
ured by both the caspase and DNA fragmentation assays.
Thus, the addition of UV-irradiation to the vaccine prepa-
ration protocol not only decreases the 3H-thymidine
incorporation of the tumor cells such that it is more likely
they will pass the release criteria, but it also enhances
apoptosis which may increase the likelihood of uptake by
dendritic cells with the subsequent presentation of tumor
antigens [45].
A potential consequence of tumor cells beginning to
undergo apoptosis and subsequent death is the degrada-
tion of cellular proteins by lysosomal proteases which
could destroy antigens that would otherwise be acquired
by dendritic cells. This in turn may prevent the subsequent
cross-priming of T cells [46,47]. Therefore, we used
immunohistochemistry to assess the expression of typical
cellular proteins after gamma-irradiation and UV-irradia-
tion (Table 1). Expression of gp100, MART-1/MelanA,
and S100 was unaffected by gamma- or UV-irradiation.
Conversely, tyrosinase expression was decreased by UV-
irradiation alone or in combination with gamma-irradia-
tion, but not by gamma-irradiation alone. T311, the anti-
body used to detect tyrosinase, binds to a linear epitopeBMC Cancer 2008, 8:360 http://www.biomedcentral.com/1471-2407/8/360
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located within amino acids 233–247 of the protein [48].
Therefore, the most likely explanations for a loss of reac-
tivity in immunohistochemistry is that the linear epitope
has been cleaved and is no longer recognized by the anti-
body, or that the protein has been degraded to such an
extent that proteolytic fragments containing the epitope
no longer exist. To further investigate the possibility that
the protein has been degraded we performed a Western
blot analysis using the polyclonal antibody H-109 which
was raised against amino acids 421–529 at the C-terminus
of the tyrosinase protein (product insert). This analysis
also showed that tyrosinase expression was greatly
reduced in UV-irradiated cells. Taken together, these
results suggest that the tyrosinase protein is not merely
unfolded, but has undergone significant degradation.
Should T cell stimulation occur as a result of recognition
of processed peptide on the irradiated tumor cells rather
than through cross priming on dendritic cells, it is possi-
ble that the loss of the epitope recognized by the antibody
could be accompanied by an increase in peptide presenta-
tion by class I MHC molecules as the denatured/degraded
protein may be processed more efficiently by proteas-
omes. These results indicate that additional studies are
warranted to determine how irradiation, apoptosis, and
necrosis affect antigen expression and the activation of
antigen-specific T cells.
Conclusion
When autologous melanoma cell vaccines are treated with
200 Gy of gamma-irradiation, 25% of them fail a lot
release criterion requiring that 3H-thymidine incorpora-
tion of the irradiated samples be less than 5% of that seen
in the non-irradiated controls. This release criterion could
be met in all samples tested, however, when gamma-irra-
diation of the cells was supplemented with UV-irradia-
tion. The results also indicate that UV-irradiation resulted
in the degradation of at least one antigen in the treated
cells, while preserving at least three other antigens. There
are currently no standard lot release criteria for autolo-
gous melanoma vaccines, but we hope the current find-
ings are informative toward future cell-based vaccine
development.
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